Business Context and Reporting Period
This Form 8-K, filed on October 2, 2024, reports on events occurring on September 26, 2024. The registrant is Reneo Pharmaceuticals, Inc. (RPHM), an emerging growth company. The filing details the results of a special meeting of stockholders held to approve a business combination with OnKure, Inc. (OnKure). Upon completion, OnKure will become a wholly-owned subsidiary of Reneo (referred to as "NewCo").
Key Financial Metrics
This filing is a current report regarding corporate governance and voting results; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for the reporting period.
Material Changes and Voting Results
At the special meeting, 21,978,803 shares were represented, constituting a quorum out of 33,428,808 outstanding shares. Stockholders approved all seven proposals necessary to effect the merger and related corporate actions:
- Proposal 1 (Merger Approval): Approved with 21,866,422 votes For, 110,625 Against, and 1,756 Abstain.
- Proposal 2 (PIPE Investment): Approved with 21,866,741 votes For, 110,676 Against, and 1,386 Abstain.
- Proposal 3 (Amended Certificate of Incorporation): Approved with 21,866,731 votes For, 110,711 Against, and 1,361 Abstain.
- Proposal 4 (Reverse Stock Split): Approved with 21,845,062 votes For, 131,855 Against, and 1,886 Abstain.
- Proposal 5 (2024 Equity Incentive Plan): Approved with 17,484,682 votes For, 4,492,498 Against, and 1,623 Abstain.
- Proposal 6 (2024 Employee Stock Purchase Plan): Approved with 18,384,090 votes For, 3,593,950 Against, and 763 Abstain.
- Proposal 7 (Adjournment): Approved, though adjournment was not necessary as other proposals passed.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the structure, timing, and completion of the merger. Management notes that actual results may differ materially due to risks and uncertainties, including the risk that conditions to the closing of the merger are not satisfied. The filing explicitly disclaims any obligation to update these forward-looking statements. No specific financial guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the final closing date of the merger between Reneo and OnKure.
- Confirm the execution of the Reverse Stock Split and the resulting share count.
- Review the definitive proxy statement/prospectus filed on August 26, 2024, for detailed terms of the PIPE investment and equity plans.
- Monitor subsequent filings for the official name change of the combined entity ("NewCo").
- Check for any conditions precedent to the merger that may still need to be satisfied or waived.